Clearstead Advisors’s Definium Therapeutics DFTX Stock Holding History

Clearstead Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$660	Buy	+14	New	+$346	﹤0.01%	2838
2022 Q4	–	Sell	-10	Closed	–	–	1353
2022 Q3	$0	Hold	10	–	–	﹤0.01%	1318
2022 Q2	$0	Sell	10 -284	-97%	-$3.59K	﹤0.01%	1379
2022 Q1	$5K	Hold	294	–	–	﹤0.01%	1079
2021 Q4	$6K	Buy	294 +84	+40%	+$2.68K	﹤0.01%	979
2021 Q3	$8K	Buy	210 +10	+5%	+$432	﹤0.01%	974
2021 Q2	$10K	Buy	+200	New	+$10.5K	﹤0.01%	799

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Clearstead Advisors's DFTX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 14 shares worth $660. The stake represents ﹤0.01% of the portfolio and ranks #2838 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in DFTX as recently as Q3 2022.

Clearstead Advisors first reported a position in DFTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $10K in Q2 2021. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Clearstead Advisors held 14 shares of Definium Therapeutics worth $660 as of Q2 2026.
Definium Therapeutics was a new Clearstead Advisors position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2838 holding.
Clearstead Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 7 quarters since.
Clearstead Advisors's Definium Therapeutics position peaked at $10K in Q2 2021.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.